Search: WFRF:(Garcia Gregory M.) > (2010-2014) > Outcomes of apixaba...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 03557naa a2200493 4500 | |
001 | oai:DiVA.org:uu-207640 | |
003 | SwePub | |
008 | 130917s2013 | |||||||||||000 ||eng| | |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-2076402 URI |
024 | 7 | a https://doi.org/10.1093/eurheartj/eht1352 DOI |
040 | a (SwePub)uu | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a Al-Khatib, Sana M.4 aut |
245 | 1 0 | a Outcomes of apixaban vs. warfarin by type and duration of atrial fibrillation :b results from the ARISTOTLE trial |
264 | c 2013-04-17 | |
264 | 1 | b Oxford University Press (OUP),c 2013 |
338 | a print2 rdacarrier | |
520 | a It is uncertain whether the benefit from apixaban varies by type and duration of atrial fibrillation (AF). A total of 18 201 patients with AF [2786 (15.3) with paroxysmal and 15 412 (84.7) with persistent or permanent] were randomized to apixaban or warfarin. In this pre-specified secondary analysis, we compared outcomes and treatment effect of apixaban vs. warfarin by AF type and duration. The primary efficacy endpoint was a composite of ischaemic or haemorrhagic stroke or systemic embolism. The secondary efficacy endpoint was all-cause mortality. There was a consistent reduction in stroke or systemic embolism (P for interaction 0.71), all-cause mortality (P for interaction 0.75), and major bleeding (P for interaction 0.50) with apixaban compared with warfarin for both AF types. Apixaban was superior to warfarin in all studied endpoints, regardless of AF duration at study entry (P for all interactions 0.13). The rate of stroke or systemic embolism was significantly higher in patients with persistent or permanent AF than patients with paroxysmal AF (1.52 vs. 0.98; P 0.003, adjusted P 0.015). There was also a trend towards higher mortality in patients with persistent or permanent AF (3.90 vs. 2.81; P 0.0002, adjusted P 0.066). The risks of stroke, mortality, and major bleeding were lower with apixaban than warfarin regardless of AF type and duration. Although the risk of stroke or systemic embolism was lower in paroxysmal than persistent or permanent AF, apixaban is an attractive alternative to warfarin in patients with AF and at least one other risk factor for stroke, regardless of the type or duration of AF. | |
653 | a Paroxysmal atrial fibrillation | |
653 | a Persistent atrial fibrillation | |
653 | a Permanent atrial fibrillation | |
653 | a Apixaban | |
653 | a Stroke | |
653 | a Major bleeding | |
700 | 1 | a Thomas, Laine4 aut |
700 | 1 | a Wallentin, Larsu Uppsala universitet,Uppsala kliniska forskningscentrum (UCR)4 aut0 (Swepub:uu)larswall |
700 | 1 | a Lopes, Renato D.4 aut |
700 | 1 | a Gersh, Bernard4 aut |
700 | 1 | a Garcia, David4 aut |
700 | 1 | a Ezekowitz, Justin4 aut |
700 | 1 | a Alings, Marco4 aut |
700 | 1 | a Yang, Hongqui4 aut |
700 | 1 | a Alexander, John H.4 aut |
700 | 1 | a Flaker, Gregory4 aut |
700 | 1 | a Hanna, Michael4 aut |
700 | 1 | a Granger, Christopher B.4 aut |
710 | 2 | a Uppsala universitetb Uppsala kliniska forskningscentrum (UCR)4 org |
773 | 0 | t European Heart Journald : Oxford University Press (OUP)g 34:31, s. 2464-2471q 34:31<2464-2471x 0195-668Xx 1522-9645 |
856 | 4 | u https://academic.oup.com/eurheartj/article-pdf/34/31/2464/17896031/eht135.pdf |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-207640 |
856 | 4 8 | u https://doi.org/10.1093/eurheartj/eht135 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
Copy and save the link in order to return to this view